$ARMP Breaking out today possible 200% gain

*****************armata-pharmaceuticals-announces-publication-of-successful-adjunctive-phage-treatment-in-cystic-fibrosis-patient**************


Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains